Cited by 43DNA Repair MechanismsMetal complexes synthesis and propertiesCancer therapeutics and mechanisms

Identification of the first small-molecule inhibitor of the REV7 DNA repair protein interaction

Open access
Actis, Marcelo L., Ambaye, Nigus D., Evison, Benjamin J., Shao, Youming, Vanarotti, Murugendra, Inoue, Akira, McDonald, Ezelle T., Kikuchi, Sotaro +4 more·2016·Bioorganic & Medicinal Chemistry

Abstract

DNA interstrand crosslink (ICL) repair (ICLR) has been implicated in the resistance of cancer cells to ICL-inducing chemotherapeutic agents. Despite the clinical significance of ICL-inducing chemotherapy, few studies have focused on developing small-molecule inhibitors for ICLR. The mammalian DNA polymerase ζ, which comprises the catalytic subunit REV3L and the non-catalytic subunit REV7, is essential for ICLR. To identify small-molecule compounds that are mechanistically capable of inhibiting ICLR by targeting REV7, high-throughput screening and structure-activity relationship (SAR) analysis were performed. Compound 1 was identified as an inhibitor of the interaction of REV7 with the REV7-binding sequence of REV3L. Compound 7 (an optimized analog of compound 1) bound directly to REV7 in nuclear magnetic resonance analyses, and inhibited the reactivation of a reporter plasmid containing an ICL in between the promoter and reporter regions. The normalized clonogenic survival of HeLa cells treated with cisplatin and compound 7 was lower than that for cells treated with cisplatin only. These findings indicate that a small-molecule inhibitor of the REV7/REV3L interaction can chemosensitize cells by inhibiting ICLR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bmc.2016.07.026

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Inhibiting the mutagenic branch of TLS by disrupting pol ζ and Rev1 protein interactions is a strategy.

    “Another strategy is to inhibit the mutagenic branch of TLS by disrupting pol ζ and Rev1 protein interactions [118,119]”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 39 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Actis, M. L., Ambaye, N. D., Evison, B. J., Shao, Y., Vanarotti, M., Inoue, A., McDonald, E. T., Kikuchi, S., Heath, R., Hara, K., Hashimoto, H., & Fujii, N.
Affiliations
  • St. Jude Children's Research Hospital (US)
  • Shizuoka University (JP)
Corresponding author
Fujii, Naoaki
Venue
Bioorganic & Medicinal Chemistry
Publisher
Elsevier BV
Published
2016-09
Volume
24
Issue
18
Pages
4339-4346
ISSN
0968-0896 (ISSN-L)
OpenAlex
W2494938857
Cited by
42
References
39
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2023: 7 · 2021: 7 · 2020: 9 · 2019: 4 · 2018: 2 · 2017: 5
FWCI
1.91
Type
journal article
Language
en
Open access
Locations
  • Bioorganic & Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American Cancer Society (CDD-120969)
  • American Lebanese Syrian Associated Charities
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
REV7, REV3L, DNA polymerase zeta, interstrand crosslink repair, small molecule inhibitors, protein-protein interaction inhibition, cisplatin resistance, chemosensitization, structure-activity relationship, HeLa cells, clonogenic survival
MeSH terms
Antineoplastic Agents, Cisplatin, DNA-Directed DNA Polymerase, DNA Repair, DNA-Binding Proteins, HeLa Cells, Humans, Protein Binding, Pyrimidinones, Structure-Activity Relationship, Thiophenes, Drug Resistance, Neoplasm, Mad2 Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review